ORIGINAL_ARTICLE
Serum Endostatin Levels in Oral Squamous Cell Carcinoma
Introduction: Endostatin is a C-terminal proteolytic fragment of collagen XVIII and, as with angiostatin and thrombospondin, is known as an antiangiogenic agent. The aim of this study was to assess the level of serum endostatin in patients with oral squamous cell carcinoma (SCC), and its association with the clinicopathological characteristics of the tumor. Materials and Methods: Using an enzyme-linked immunosorbent assay (ELISA) kit, we investigated the circulating levels of endostatin in the blood serum of 45 patients with oral SCC and 45 healthy controls. Results: The mean level of serum endostatin in patients was significantly lower (68.8±85 ng/ml) than in healthy controls (175.6±73 ng/ml) (P<0.001). Serum endostatin levels were significantly lower in patients with lymph node metastasis compared with patients without lymph node metastasis (P<0.001). In addition, serum endostatin level was associated with higher histological grade (P<0.001). There were no apparent correlations between serum endostatin concentration and clinicopathological features such as age, gender, and tumor stage (P>0.05). Conclusion: Findings of the present study suggest the prognostic and anti-metastatic role of endostatin, and this may be used as a tool for monitoring tumor progression.
https://ijorl.mums.ac.ir/article_10696_e0413553c708b504c65fa8de463582aa.pdf
2018-05-01
125
130
10.22038/ijorl.2018.25759.1850
Endostatin
Mouth
Serum
Squamous cell carcinoma
Maryam
Mardani
mardanim@sums.ac.ir
1
Oral and Dental Disease Research Center, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.
AUTHOR
Azadeh
Andisheh-Tadbir
andisheh202003@yahoo.com
2
Oral and Dental Disease Research Center, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.
AUTHOR
Mohammad Ali
Ranjbar
dr.ranjbar60@yahoo.com
3
Department of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.
LEAD_AUTHOR
Bijan
Khademi
khademib@sums.ac.ir
4
Department of Otolaryngology, Khalili Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
AUTHOR
Mohammad Javad
Fattahi
fattahimj@sums.ac.ir
5
Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran.
AUTHOR
Ahmad
Rahbar
rahbara@sums.ac.ir
6
Undergraduate Student, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.
AUTHOR
1. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009; 45: 309–16.
1
2. Wang ZH, Zhu ZT, Xiao XY, Sun J. Correlation of Serum Levels of Endostatin with Tumor Stage in Gastric Cancer: A Systematic Review and Meta-Analysis Biomed Res Int. 2015;2015:623939.
2
3. ZhuwW, Che Y, Song X, Luo Y. Endostatin specifically targets both tumor blood vessels and lymphatic vessels. Front Med. 2011;5:336–40.
3
4. O'Reilly MS, Boehm T, ShingY, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277–85.
4
5. Taddei L, Chiarugi P, Brogelli L, Cirri P, Magnelli L, Raugei G, et al. Inhibitory effect of full-length human endostatin on in vitro angiogenesis. Biochem Biophys Res Commun. 1999; 263:340–5.
5
6. Dhanabal M, Ramchandran R, Waterman MJF, Lu H, Knebelmann B, Segal M, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem. 1999;274:11721–6.
6
7. Jiang WG, Lu XA, Shang BY, Fu Y, Zhang SH, Zhou D, et al. Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis. BMC: Cancer. 2013;13: 479.
7
8. Wan YY, Tian GY, Guo HS, Kang YM, Yao ZH, Li XL, et al. Endostatin, an angiogenesis inhibitor, ameliorates bleomycin-induced pulmonary fibrosis in rats. Respir Res. 2013;14:56.
8
9. Zhuo W, Luo C, Wang X, Song X, Fu Y, Luo Y. Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells. J Pathol. 2010;222:249–60.
9
10. Bai YJ, Huang LZ, Zhou AY, Zhao M, Yu WZ, Li XX. Antiangiogenesis effects of endostatin in retinal neovascularization. J Ocul Pharmacol Ther. 2013;29:619–26.
10
11. Feldman AL, Alexander HR Jr, Bartlett DL, Kranda KC, Miller MS, Costouros NG, et al. A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases. Ann Surg Oncol. 2001;8:741–5.
11
12. Feldman AL, Alexander HR Jr, Yang JC, Linehan WM, Eyler RA, Miller MS, et al. Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer. 2002;95:1637–43.
12
13. Hata K, Dhar DK, Kanasaki H, Nakayama K, Fujiwaki R, Katabuchi H, et al. Serum endostatin levels in patients with epithelial ovarian cancer. Anticancer Res. 2003;23:1907–12.
13
14. Bono P, Teerenhovi L, Joensuu H. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma. Cancer. 2003;97:2767–75.
14
15. Suzuki M, Izasa T, Ko E, Baba M, Saitoh Y, Shibuya K, et al. Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. Lung Cancer. 2002;35:29–34.
15
16. Mo HY, Luo DH, Qiu HZ, Liu H, Chen QY, Tang LQ. Elevated serum endostatin levels are associated with poor survival in patients with advanced-stage nasopharyngeal carcinoma. Clin Oncol. 2013;25(5):308–17.
16
17. Kantola T, Väyrynen JP, Klintrup K, Mäkelä J, Karppinen SM, Pihlajaniemi T, et al. Serum endostatin levels are elevated in colorectal cancer and correlate with invasion and systemic inflammatory markers. Br J Cancer. 2014; 111: 1605–13.
17
18. Szarvas T, László V, VomDorp F, Reis H, Szendröi A, Romics I, et al. Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients' prognosis in bladder cancer. Int J Cancer. 2012;130:2922–9.
18
19. Greene FL, Compton CC, Fritz AG, Shah JP, Winchester DP. Lip and oral cavity. In: AJCC cancer staging atlas. 6th ed. New York: Springer; 2006.19–26.
19
20. Sharma BK, Srinivasan R, Kapil S, Singla B, Saini N, Chawla YK, et al. Serum levels of angiogenic and anti-angiogenic factors: their prognostic relevance in locally advanced hepatocellular carcinoma. Mol Cell Biochem. 2013; 383:103–12.
20
21. O'Byrne KJ, Dalgleish AG, Browning MJ, Steward WP, Harris AL. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer. 2000;36:151–69.
21
22. Homer JJ, Greenman J, Stafford ND. Circulating angiogenic cytokines as tumour markers and prognostic factors in head and neck squamous cell carcinoma. Clin Otolaryngol Allied Sci. 2002;27:32–37.
22
23. Nikitakis NG, Rivera H, Lopes MA, Siavash H, Reynolds MA, Ord RA, et al.Immunohistochemical Expression of Angiogenesis-Related Markers in oral squamous cell carcinomas with multiple metastatic lymph nodes. Am J Clin Pathol. 2003;119:574–86.
23
24. Fukumoto S, Morifuji M, Katakura Y, Ohishi M, Nakamura S. Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells. Clin Exp Metastasis. 2005;22:31–8.
24
25. Onogawa S, Kitadai Y, Tanaka S, Kuwai T, Kimura S, Chayama K, et al. Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci. 2004; 95: 32–9.
25
26. Amioka T, Kitadai Y, Tanaka S, Haruma K, Yoshihara M, Yasui W, et al. Vascular endothelial growth factor-C expression predicts lymph node metastasis of human gastric carcinomas invading the submucosa. Eu J Cancer. 2002;38:1413–9.
26
27. Neuchrist C, Erovic BM, Handisurya A, Fischer MB, Steiner GE, Hollemann D, et al. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck. Head Neck. 2003;25:464–74.
27
28. Kitadai Y, Amioka T, Haruma K, Tanaka S, Yoshihara M, Sumii K, et al. Clinicopathological significance of vasucular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int J Cancer. 2001;93:662–6.
28
29. Shao XJ, Xie FM. Influence of angiogenesis inhibitors, endostatin and PF-4, on lymphangiogenesis. Lymphology. 2005;38:1–8.
29
30. Sund M, Hamano Y, Sugimoto H, Sudhakar A, Soubasakos M, Yerramalla U, et al. Function of endogenous inhibitors of angiogenesis as endothelium specific tumor suppressors. Proc Natl Acad Sci USA. 2005;102:2934–9.
30
31. Li C, Harris MB, Venema VJ, Venema RC. Endostatin induces acute endothelial nitric oxide and prostacyclin release. Biochem Biophys Res Commun. 2005;329:873–8.
31
32. Celik I, Sürücü O, Dietz C, Heymach JV, Force J, Höschele I, et al. Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res. 2005;65:11044–50.
32
33. Tjin Tham Sjin RM, Naspinski J, Birsner AE, Li C, Chan R, Lo K-M, et al. Endostatin therapy reveals a U-shaped curve for antitumor activity. Cancer Gene Ther. 2006;13:619–27.
33
34. Nyberg P, Heikkilä P, Sorsa T, Luostarinen J, Heljasvaara R, Stenman UH, et al. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13. J Biol Chem. 2003; 278: 22404–11.
34
35. Kim YM, Jang JW, Lee OH, Yeon J, Choi EY, Kim KW,et al. Endostatin Inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase 2. Cancer Res. 2000;60:5410–3.
35
36. Lee SJ, Jang JW, Kim YM, Lee HI, Jeon JY, Kwon YG, et al. Endostatin binds to the catalytic domain of matrix metalloproteinase-2. FEBS Lett. 2002;519:147–52.
36
37. Gao SR, Li LM, Xia HP, Wang GM, Xu HY, Wang AR. Clinical observation on recombinant human endostatin combined with chemotherapy for advanced gastrointestinal cancer. Asian Pac J Cancer Prev. 2015;16:4037–40.
37
ORIGINAL_ARTICLE
Patient-Based Assessment of Effectiveness of Voice Therapy in Vocal Mass Lesions with Secondary Muscle Tension Dysphonia
Introduction: Use of patient-based voice assessment scales is an appropriate method that is frequently used to demonstrate effectiveness of voice therapy. This study was aimed at determining the effectiveness ofvoice therapy among patients with secondary muscle tension dysphonia (MTD) and vocal mass lesions. Materials and Methods: The study design was prospective, with within-participant repeated measures. Thirty-three patients with secondary MTD and vocal mass lesions participated in the study, selected on the basis of voice history, laryngeal palpation, and videostroboscopy examination. An experienced otolaryngologist and one experienced speech language pathologist undertook the diagnostic process. Voice therapy included both direct and indirect techniques and lasted approximately 2 months for all included patients. The voice handicap index (VHI) was used to evaluate the effectiveness ofvoice therapy among included patients. Paired t-test, size of the standardized effect (ESI),and mean standardized response (ESII) were used to analyze effectiveness of the target voice therapy. Results: The findings of this study indicate astatistically significant improvement after the voice therapy protocol (P<0.05; t>1.96). Results of ESI and ESII demonstrate that the VHI scale is sufficiently responsive to detect voice therapy change (ES>0.8). Conclusion: This study recommends a combination of direct and indirect voice therapy in the vocal rehabilitation of patients with secondary MTD and vocal mass lesions. Furthormore, we recommend use of the VHI scale to show voice therapy changes for both clinical and research purposes.
https://ijorl.mums.ac.ir/article_10697_c6a792c2c03a9626847a5146e7c4ae56.pdf
2018-05-01
131
137
10.22038/ijorl.2018.27299.1895
Muscle tension dysphonia
Voice handicap index
Vocal mass lesions
Voice therapy
Ahmad Reza
Khatoonabadi
khatoonabadi@tums.ac.ir
1
Department of Speech Therapy, School of Rehabilitation, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
Hassan
Khoramshahi
hany552ir@yahoo.com
2
Musculoskeletal Rehabilitation Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; Department of Speech Therapy, School of Rehabilitation, Tehran University of Medical Sciences, Tehran, Iran.
LEAD_AUTHOR
Seyyedeh Maryam
Khoddami
khoddami@tums.ac.ir
3
Department of Speech Therapy, School of Rehabilitation, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
Peyman
Dabirmoghaddam
peyman.dm@gmail.com
4
Otorhinolaryngology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
Noureddin Nakhostin
Ansari
nakhostin@tums.ac.ir
5
Department of Physiotherapy, School of Rehabilitation, Tehran University of Medical Sciences, Tehran, Iran; Sports Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
1. Dejonckere PH, Clemente P, Cornut G, Crevier Buchman L, Friedrich G, Van De Heyning, et al. A basic protocol for functional assessment of voice pathology, especially for investigating the efficacy of (phonosurgical) treatments and evaluating new assessment techniques. Eur Arch Otorhinolaryngol. 2001; 258: 77–82.
1
2. Kreiman J, Gerratt BR, Kempster G, Erman A, Berke G. Perceptual Evaluation of Voice Quality: Review, Tutorial, and a Framework for Future Research. J Speech Hear Res.1993;36:31–2.
2
3. Helou LB, Solomon NP, Henry LR, Coppit GL, Howard RS, Stojadinovic A. The role of listener experience on Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V) ratings of post-thyroidectomy voice. Am J Speech Lang Pathol. 2010; 19:249–53.
3
4. Zraick RI, Kempster GB, Connor NP, Klaben BK, Bursac Z, Glaze LE. Establishing validity of the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V). Am J Speech Lang Pathol. 2011; 20: 16–17.
4
5. Karnell MP, Melton SD, Childes JM, Coleman TC, Dailey SA, Hoffman HT. documentation of voice disorders. J Voice. 2006;21:576–90.
5
6.Moradi N, Porshahabaz A, Soltani M, Javadipour S, Hashemi H, Soltaninejad N. Cross-cultural equivalence and evaluation of psychometric properties of voice handicap index into Persian. J Voice. 2013;27:258.
6
7. Seifpanahi S, Jalaie S, Nikoo MR, Sobhani-Rad D. Translated Versions of Voice Handicap Index (VHI)-30 across Languages: A Systematic Review. Iran J Public Health. 2015 44(4):458–69.
7
8. Jacobson BH, Johnson A, Grywalski C, Silbergleit A, Jacobson G, Benninger MS, et al. The Voice Handicap Index (VHI): Development and Validation.AJSLP. 1997;6:66–70.
8
9. Rosen CA, Murry T, Zinn A, Zullo T, Sonbolian M. Voice handicap index change following treatment of voice disorders. J Voice. 2000; 14(4): 619-23.
9
10. Bouwers F, Dikkers FG. A retrospective study concerning the psychosocial impact of voice disorders: Voice Handicap Index change in patients with benign voice disorders after treatment (measured with the Dutch version of the VHI). J Voice. 2009;23:218–24.
10
11. Stuut M, Tjon Pian Gi RE, Dikkers FG. Change of Voice Handicap Index after treatment of benign laryngeal disorder. Eur Arch Otorhinolaryngol. 2014; 271:1157–62.
11
12.Craig J, Tomlinson C, Stevens K, Kotagal K, Fornadley J, Jacobson B, Garrett CG, Francis DO. Combining voice therapy and physical therapy: A novel approach to treating muscle tension dysphonia. J Commun Disord. 2015;58:169–78.
12
13. Tezcaner CZ, Karatayli Ozgursoy S, Sati I, Dursun G. Changes after voice therapy in objective and subjective voice measurements of pediatric patients with vocal nodules. Eur Arch Otorhinolaryngol. 2009;266:1923–7.
13
14. Thomas G, Mathews SS, Chrysolyte SB, Rupa V.Outcome analysis of benign vocal cord lesions by videostroboscopy, acoustic analysis and voice handicap index. Indian J Otolaryngol Head Neck Surg. 2007;59:336–40.
14
15. Rosen CA, Gartner-Schmidt J, Hathaway B, Simpson CB, Postma GN, Courey M, et al. A nomenclature paradigm for benign midmembra- nous vocal fold lesions. Laryngoscope. 2012; 122: 1335–41.
15
16. Wang CT, Lai MS, Hsiao TY. Comprehensive Outcome Researches of Intralesional Steroid Injection on Benign Vocal Fold Lesions. J Voice. 2015; 29:578–87.
16
17. Dailey SH, Spanou K, Zeitels SM. The evaluation of benign glottic lesions:rigid telescopic stroboscopy versus suspension microlaryngoscopy. J Voice. 2007;21:112–18.
17
18. Cho JH, Choi YS, JOO YH, Park YH, Sun DI. Clinical Significance of Contralateral Reactive Lesion in Vocal Fold Polyp and Cyst. J Voice. 2018; 32:109–15.
18
19. Van Houtte E, Van Lierde K, D’haeseleer E, Claeys S. The prevalence of laryngeal pathology in a treatment seeking population. J Voice. 2013; 27: 177–86.
19
20. Verdolini K, Rosen, Branski RC. Classification Manual for Voice Disorders-I.1st Edition. Psychology Press; 2006.
20
21. Boone D, McFarlane S, Vonberg S. The voice and voice therapy. 7th ed. United States of America: Pearson Education; 2005.
21
22. Stemple JC, Roy N, Klaben BK. Clinical Voice Pathology. Fifth Edition. Plural Publication; 2014.17.
22
23. Colton R, Casper J, Leonard R. Understanding voice problems: A Physiological Perspective for Diagnostic for Diagnostic and Treatment. 4th ed. Lippincott Williams & Wilkins; 2006.
23
24. Aronson AE. Clinical Voice Disorders: An Interdisciplinary Approach, 3rd ed. New York: Thieme Stratton; 1990.
24
25. Roy N, Leeper HA. Effects of the manual laryngeal musculoskeletal tension reduction technique as a treatment for functional voice disorders: perceptual and acoustic measures. J Voice. 1993;7:242–9.
25
26. Roy N, Bless DM, Heisey D, Ford CN. Manual circumlaryngeal therapy for functional dysphonia: an evaluation of short- and long-term treatment outcomes. J Voice. 1997;11:321–31.
26
27. Van Lierde KM, De Ley S, Clement G, Bodt De, Van Cauwenberge P. outcome of laryngeal manual therapy in four Dutch adults with persistent moderate-to-severe vocal hyperfunction: a pilot study. J Voice. 2004;18:467–74.
27
28. Carding PN, Horsley IA, Docherty GJ. A study of the effectiveness of voice therapy in the treatment of 45 patients with nonorganic dysphonia. J Voice. 1999; 13:72–104.
28
29. Ruotsalainen JH, Sellman J, Letho L, Jauhiainen M, Verbeek JH. Interventions for treating functional dysphonia in adults. Cochrane Database Syst Rev. 2007; 3:CD006373.
29
30. Ruotsalainen JH, Sellman J, Lehto L, Verbeek J. Systematic review of the treatment of functional dysphonia and prevention of voice disorders. Otolaryngol Head Neck Surg. 2008;138:557–65.
30
31. Verdolini Abbott K. Lessac-Madsen Resonant Voice Therapy. Oxfordshire,UK: Plural Publishing Inc; 2008.
31
32. Van Houtte E, Van Lierde K, and Sofie Claeys Pathophysiology and Treatment of Muscle Tension Dysphonia: A Review of the Current Knowledge. J Voice.2011;25:202–7.
32
33. Angsuwarangsee T, Morrrison M. Extrinsic Laryngeal muscular tension in patients with voice disorders. J Voice. 2002;16:333–43.
33
34. Carter R, Lubinsky J, Domholdt E. Rehabilitation Resaerch. 4the ed. United State of America: Elsevier Saunders. 2009.
34
35. de Yébenes Prous MJ1, Rodríguez Salvanés F, Carmona Ortells L. Responsiveness of Outcome Measures. ReumatolClin. 2008;4:240–7.
35
36. Beaton DE, Bombardier C, Katz JN, Wright JG. A taxonomy for responsiveness. J Clin Epidemiol. 2001;54:1204–17.
36
37. Husted JA, Cook RJ, Farewell VT, Gladman DD. Methods for assessing responsiveness: a critical review and recommendations. J Clin Epidemiol. 2000;53:459–68.
37
38. Stratford PW, Riddle DL. Assessing sensitivity to change: choosing the appropriate change coefficient. Health Qual Life Outcomes. 2005;3:23.
38
39. Norman GR, Stratford P, Regehr G. Methodological problems in the retrospective computation of responsiveness to change: the lesson of Cronbach. J Clin Epidemiol. 1997; 50:869–79.
39
40. Deyo RA, Centor RM. Assessing the responsiveness of functional scales to clinical change: an analogy to diagnostic test performance. J Chron Dis. 1986;39: 897–906.
40
41. Khoramshahi H, Khatoonabadi AZ, Khoddami SM, Dabirmoghaddam P, Ansari NN. Responsiveness of Persian Version of Consensus Auditory Perceptual Evaluation of Voice (CAPE-V), Persian Version of Voice Handicap Index (VHI), and Praat in Vocal Mass Lesions with Muscle Tension Dysphonia. J Voice.2017; article in press.
41
ORIGINAL_ARTICLE
Evaluating the Effect of Endoscopic Sinus Surgery on Laryngeal Mucosa Stroboscopic Features
Introduction:
The major presenting symptom of nasal polyps is nasal obstruction. The role of nasal obstruction in the genesis of laryngeal disorders is still unknown.
Materials and Methods:
The aim of this study was to evaluate laryngeal videostroboscopic changes after functional endoscopic sinus surgery (FESS) in patients with nasal polyposis. A longitudinal study was carried out from March 2012 to June 2013. Thirty patients with bilateral nasal polyposis who did not respond to maximum medical treatment and were candidates for FESS were recruited. Laryngeal videostroboscopy was performed before and 3 months after FESS. Glottic gap, true vocal cord (TVC) borders and pliability, false vocal cord (FVC) movement, laryngeal erythema and mucosal edema were documented.
Results:
Laryngeal erythema and TVC edema were significantly decreased after FESS. Laryngeal erythema was documented in 18 patients after a 3-month follow-up. Four patients (13.3%) showed mild-to-moderate TVC edema and 26 patients (86.7%) had normal TVC mucosa.
Conclusion:
The results of this study show that FESS has a significant impact on laryngeal videostroboscopic features including laryngeal erythema and TVC edema.
https://ijorl.mums.ac.ir/article_10698_08379b94bab17f0e219e5e0f874ea73b.pdf
2018-05-01
139
143
10.22038/ijorl.2018.25089.1815
Endoscopy
Erythema
Edema
Laryngoscopy
Nasal Polyps
Nasal obstruction
Stroboscopy
Ebrahim
Karimi
karimient@gmail.com
1
Otorhinolaryngology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
Akbar
Bayat
bayatakbar@yahoo.com
2
Otorhinolaryngology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
Mohammad Reza
Ghahari
mr6hahari@yahoo.com
3
Otorhinolaryngology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
Sara
Rahavi-Ezabadi
s-rahavi@student.tums.ac.ir
4
Otorhinolaryngology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
Mehrdad
Jafari
mehrdadj82@yahoo.com
5
Otorhinolaryngology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
LEAD_AUTHOR
I. Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999;28:717–22.
1
2. Laren PL, Tos M. Anatomic site of origin of nasal polyps: endoscopic nasal and paranasal sinus surgery as a screening method for nasal polyps in autopsy material. Rhinology 1994; 33:185–8.
2
3. Gleeson M, Browning GG, Butron MJ, Clarke RW, Hibbert J, Lond VJ. Scott-Brown's Otolaryngology. 7th Edition. Great Britain: Hodder Arnold; 2008: Vol. 2. Rhinology, 1549–59.
3
4. Cecil M, Tindall M, Haydon R. The relationship between dysphonia and sinusitis: a pilot study. J Voice 2001;15 ):270–77.
4
5. Meirelles RG. Obstrucao nasal e nodulosvocais. Rev Bras Otorrinolaringol. 2001;67:387–392.
5
6. De Labio RB, Tavares EL, Alvarado RC, Martins RJ-1. Consequences of chronic nasal obstruction on the laryngeal mucosa and voice quality of 4 to 12-year-old children. J Voice 2011; 26:488–92.
6
7. Bless DM, Hirano M, Feder RJ. Videostrobosco- pic evaluation of the larynx. Ear Nose Throat J. 1987;66:289–96.
7
8. Colton RH, Casper JK. Understanding voice problems: a physiological perspective for diagnosis and treatment. Philadelphia: Lippincott Williams & Wilkins; 1996. p. 358.
8
9. Gomaa MA, Mohammed HM, Abdalla AA, Nasr OM. Effect of adenoid hypertrophy on the voice and laryngeal mucosa 111 children. Int J Pediatr Otorhinolaryngol. 2013;77: 1936–9.
9
10. Mora R, Jankowska B, Mora F, Crippa B, Dellepiane M, Salami A. Effects of tonsillectomy on speech and voice. J Voice. 2009;23:614–18.
10
ORIGINAL_ARTICLE
Peripheral Facial Palsy in Emergency Department
Introduction: Peripheral facial palsy (PFP) is commonly diagnosed in every emergency department. Despite being a benign condition in most cases, PFP causes loss in quality of life mostly due to facial dysmorphia. The etiology of PFP remains unknown in most cases, while medical opinion on epidemiology, risk factors and optimal treatment is not consensual. The aim of this study was to review the demographic characteristics of our patients and the medical care administered in our emergency department. Materials and Methods: Emergency episodes occurring in a 4-year period and codified as facial nerve pathology were analyzed. IBM SPSS software was used for statistical analysis. Results: In total, 582 emergency episodes were obtained. Due to inexpressive representation of other causes of PFP in our study, we focused our analyses on the 495 patients who were considered to have idiopathic PFP. There was equal distribution among genders, and all age ranges were affected. There were no clear epidemic phenomena. Hypertension was not a statistically significant risk factor for Bell's palsy. Most patients sought medical care in the early stages of the disease and complained of isolated facial weakness. Most patients had mild-to-moderate symptoms. Previous upper way infections (PUAI) were more frequent among children. There was a statistically significant difference regarding computed tomography (CT) scan requests among specialties. Conclusion: Epidemiologic findings were consistent with most literature on Bell's palsy. Drug therapy is widely used and follows current guidelines. The role of PUAI in the pediatric population must be investigated. Despite evidence of good medical practice, there was an excess of CT scans requested by physicians other than otorhinolaryngologists.
https://ijorl.mums.ac.ir/article_10699_ead2e0f36208ad27e5c751a97009c36f.pdf
2018-05-01
145
152
10.22038/ijorl.2018.24504.1803
Bell Palsy
Herpes simplex
Otorhinolaryngologic disease
Peripheral Facial paralyses
Jose
Ferreira-Penêda
jfpeneda@gmail.com
1
Department of Otorhinolaryngology, Centro Hospitalar Vila Nova de Gaia, Espinho, Portugal.
LEAD_AUTHOR
Raquel
Robles
raqrobles@hotmail.com
2
Department of Otorhinolaryngology, Centro Hospitalar Vila Nova de Gaia, Espinho, Portugal.
AUTHOR
Isabel
Gomes-Pinto
isagomespinto@gmail.com
3
Department of Otorhinolaryngology, Centro Hospitalar Vila Nova de Gaia, Espinho, Portugal.
AUTHOR
Pedro
Valente
pedrofmvalente@gmail.com
4
Department of Otorhinolaryngology, Centro Hospitalar Vila Nova de Gaia, Espinho, Portugal.
AUTHOR
Nuno
Barros-Lima
nuno.b.lima@gmail.com
5
Department of Otorhinolaryngology, Centro Hospitalar Vila Nova de Gaia, Espinho, Portugal.
AUTHOR
Artur
Condé
arturmconde@gmail.com
6
Department of Otorhinolaryngology, Centro Hospitalar Vila Nova de Gaia, Espinho, Portugal.
AUTHOR
1. Spencer C, Irving R. Causes and management of facial nerve palsy. Br J Hosp Med. 2016;77: 686–91.
1
2. Eviston T, Croxson G, Kennedy P, Hadlock T, Krishnan A. Bell’s palsy: aetiology, clinical features and multidisciplinary care. J Neurol Neurosurg Psychiatry. 2015;86:1356–61.
2
3. Ferreira M, Firmino-Machado J, Marques E, Santos P, Simões A, Duarte J. Prognostic factors for recovery in Portuguese patients with Bell’s palsy. Neurol Res. 2016;38:851–6.
3
4. Finsterer J. Management of peripheral facial nerve palsy. Eur Arch Oto-Rhino-Laryngology. 2008;265:743–52.
4
5. Monini S, Lazzarino A, Iacolucci C, Buffoni A, Barbara M. Epidemiology of Bell’s palsy in an Italian Health District: incidence and case-control study. Acta Otorhinolaryngol Ital. 2010;30:198–204.
5
6. Newadkar U, Chaudhari L, Khalekar Y. Facial palsy, a disorder belonging to influential neurological dynasty: Review of literature. N Am J Med Sci. 2016;8:263–7.
6
7. Baugh R, Basura G, Ishii L, Schwartz SR, Drumheller CM, Burkholder R, et al. Clinical Practice Guideline. Otolaryngol Neck Surg. 2013; 149:S1–S27.
7
8. Savadi-Oskouei D, Abedi A, Sadeghi-Bazargani H. Independent role of hypertension in Bell’s palsy: A case-control study. Eur Neurol. 2008; 60: 253–7.
8
9. Rowlands S, Hooper R, Hughes R, Burney P. The epidemiology and treatment of Bell’s palsy in the UK. Eur J Neurol. 2002;9:63–67.
9
10. Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51:81–100.
10
11. Murakami S, Mirzobuchi M, Nakashiro Y, Doi T, Hato N, Yanagihara N. Bell’s palsy and herpes simplex virus: identification of viral DNA in endoneural fluid and muscle. Ann Int Med. 1996; 124:27–30.
11
12. Glass G, Tzafetta K. Bell’s palsy: A summary of current evidence and referral algorithm. Fam Pract. 2014;31:631–42.
12
13. Galluzzi L, Blomgren K, Kroemer G. Mitochondrial membrane permeabilization in neuronal injury. Nat Rev Neurosci. 2009;10: 481–94.
13
14. Nichols M, Townsend N, Scarborough P, Rayner M, Leal, J, Luengo-Fernandez R, et al. European Cardiovascular Disease Statistics 2012, available online at https://www.escardio.org/The-ESC/What-we-do/Initiatives/EuroHeart/2012-European-Cardiovascular-Disease-Statistics in 08/ 06/2017.
14
15. Instituto Nacional de Estatística IP. Censos 2011 Resultados Definitivos - Portugal 2011, available on line at http://censos. ine.pt/ xportal/ xmain?xpid=CENSOS&xpgid=ine_censos_publicacoes in 08/06/2017.
15
16. Sociedade Portuguesa de Diabetologia. Diabetes: Factos E Números – O Ano de 2014 − Relatório Anual Do Observatório Nacional Da Diabetes, available on line at http:// www. spd.pt/index.php/observatrio-mainmenu-330 in 08/ 06/ 2017.
16
17. Ciorba A, Corazzi V, Conz V, Bianchini C, Aimoni C, Facial nerve paralysis in children. World J Clin Cases. 2015;3:973–9.
17
18. Wang C, Chang Y, Shih H, Chen C, Chen J. Facial Palsy in Children. Pediatr Emerg Care. 2010; 26:121–5.
18
19. Reddy S, Redett R. Facial paralysis in children. Facial Plast Surg. 2015;31:117–22.
19
20. Evans A, Licameli G, Brietzke S, Whittemore K, Kenna M. Pediatric facial nerve paralysis: Patients, management and outcomes. Int J Pediatr Otorhinolaryngol. 2005;69:1521–8.
20
21. House J, Brackmann D. Facial nerve grading system. Otolaryngol Head Neck Surg. 1985; 93: 146–7.
21
22. Kattah J, Talkad A, Wang D, Hsieh Y, Newman-Toker D. HINTS to diagnose stroke in the acute vestibular syndrome: Three-step bedside oculomotor examination more sensitive than early MRI diffusion-weighted imaging. Stroke. 2009; 40: 3504–10.
22
23. Chalela J, Kidwell C, Nentwich L, Luby M, Butman JA, Demchuk AM, et al. Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet. 2007; 369:293–8.
23
24. Kim C, Lelli G. Current considerations in the management of facial nerve palsy. Curr Opin Ophthalmol. 2013;24:478–83.
24
ORIGINAL_ARTICLE
Predictors of Thyroid Gland Invasion in Laryngeal Squamous Cell Carcinoma
Introduction: Laryngeal squamous cell carcinoma (SCC) can invade the thyroid gland leading to unnecessary thyroidectomies with subsequent hypothyroidism and hyperparathyroidism. Thus, clinicopathological variables should be defined in order to predict thyroid gland invasion preoperatively. Materials and Methods: We performed a retrospective analysis of 1,465 patients with laryngeal SCC referred to our center between March 2009 and January 2016. Among these patients, 60 individuals underwent total laryngectomy and either thyroid lobectomy and isthmectomy or total thyroidectomy. Results: Thyroid gland invasion was observed in 20% of samples. The following variables were associated with thyroid gland invasion: transglottic spread of the tumor (odds ratio [OR]: 2.04, 95% confidence interval [CI]: 1.15–5.81, P=0.004), thyroid cartilage involvement (OR: 1.53, 95% CI: 0.94–2.50, P=0.02), and anterior commissure involvement (OR: 5.75, 95% CI: 0.86–38.42, P=0.01). In addition, the largest dimension of the tumor was significantly associated with thyroid gland involvement (r=0.36, 95% CI 0.05–0.67, P=0.004). Multivariate linear regression analysis confirmed these findings. Conclusion: The rate of thyroidectomies performed in cases of laryngeal SCC is much higher than the actual rate of thyroid gland invasion. Thus, preoperative evaluation to find transglottic spread of the tumor, thyroid cartilage, and anterior commissure involvement should be considered.
https://ijorl.mums.ac.ir/article_10702_766821080184c5fe2646228e7e420d69.pdf
2018-05-01
153
158
10.22038/ijorl.2018.26046.1855
Larynx
Neoplasm invasion
Squamous cell carcinoma
Thyroid
Keyvan
Aghazadeh
aghazadeh@tums.ac.ir
1
Otorhinolaryngology Research Center, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Sasan
Dabiri satri
sasan.dabiri@gmail.com
2
Otorhinolaryngology Research Center, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Amirsina
Sharifi
a.s_sharifi@yahoo.com
3
Otorhinolaryngology Research Center, Tehran University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
Maryam
Lotfi
maryamlotfi@yahoo.com
4
Department of Pathology, Amiralam Hospital, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
Bita
Maraghehpour
bitamaraghehpour77@yahoo.com
5
International Campus, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Arsalan
Hashemiaghdam
arsalanhashemi@gmail.com
6
Faculty of medicine, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
1. Hilly O, Raz R, Vaisbuch Y, Strenov Y, Segal K, Koren R, et al. Thyroid gland involvement in advanced laryngeal cancer: Association with clinical and pathologic characteristics. Head Neck. 2012; 34(11):1586-90.
1
2. Elliott MS, Odell EW, Tysome JR, Connor SEJ, Siddiqui A, Jeannon J-P, et al. Role of thyroidectomy in advanced laryngeal and pharyngolaryngeal carcinoma. Otolaryngology--Head and Neck Surgery. 2010;142(6):851-5.
2
3. Nayak SP, Singh V, Dam A, Bhowmik A, Jadhav TS, Ashraf M, et al. Mechanism of thyroid gland invasion in laryngeal cancer and indications for thyroidectomy. Indian Journal of Otolaryngology and Head & Neck Surgery. 2013;65(1):69-73.
3
4. Dadas B, Uslu B, Çakir B, Ozdogan HC. Intraoperative management of the thyroid gland in laryngeal cancer surgery. Journal of Otolaryngology-Head & Neck Surgery. 2001;30(3):179.
4
5. Scherl C, Mantsopoulos K, Semrau S, Fietkau R, Kapsreiter M, Koch M, et al. Management of advanced hypopharyngeal and laryngeal cancer with and without cartilage invasion. Auris Nasus Larynx. 2016.
5
6. Gaillardin L, Beutter P, Cottier JP, Arbion F, Morinière S. Thyroid gland invasion in laryngopharyngeal squamous cell carcinoma: prevalence, endoscopic and CT predictors. Eur Ann Otorhinolaryngol Head Neck Dis. 2012;129(1):1-5.
6
7. Galbo AML, Kuik DJ, Lips P, von Blomberg BME, Bloemena E, Leemans CR. A prospective longitudinal study on endocrine dysfunction following treatment of laryngeal or hypopharyngeal carcinoma. Oral Oncol. 2013;49(9):950-5.
7
8.Kim JW, Han GS, Byun SS, Lee DY, Cho BH, Kim Y-M. Management of thyroid gland invasion in laryngopharyngeal cancer. Auris Nasus Larynx. 2008;35(2):209-12.
8
9. Mourad M, Saman M, Sawhney R, Ducic Y. Management of the thyroid gland during total laryngectomy in patients with laryngeal squamous cell carcinoma. The Laryngoscope. 2015; 125(8): 1835-8.
9
10. Pfister DG, Laurie SA, Weinstein GS, Mendenhall WM, Adelstein DJ, Ang KK, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol. 2006;24(22):3693-704.
10
11. Moubayed SP, Bélair M, Saliba J, Bibeau-Poirier J, Christopoulos A, Nguyen-Tan P-F, et al.
11
Prognostic value of cartilage sclerosis in laryngeal cancer treated with primary radiation therapy. Otolaryngology--Head and Neck Surgery. 2012; 147(1):57-62.
12
12. Stenson KM, MacCracken E, Kunnavakkam R, Cohen W, Ezra E, Portugal LD, et al. Chemoradiation for patients with large‐volume laryngeal cancers. Head Neck. 2012;34(8):1162-7.
13
13. Mendelson AA, Al-Khatib TA, Julien M, Payne RJ, Black MJ, Hier MP. Thyroid gland management in total laryngectomy: meta-analysis and surgical recommendations. Otolaryngology—Head and Neck Surgery. 2009;140(3):298-305.
14
14. Mangussi-Gomes J, Danelon-Leonhardt F, Moussalem GF, Ahumada NG, Oliveira CL, Hojaij FC. Thyroid gland invasion in advanced squamous cell carcinoma of the larynx and hypopharynx. Braz J Otorhinolaryngol. 2016.
15
15. Joshi P, Nair S, Chaturvedi P, Nair D, Shivakumar T, D'Cruz AK. Thyroid gland involvement in carcinoma of the hypopharynx. The Journal of laryngology and otology. 2014; 128(1): 64.
16
16. Mortimore S, Thorp MA, Nilssen ELK, Isaacs S. Hypoparathyroidism after the treatment of laryngopharyngeal carcinoma. The Journal of Laryngology & Otology. 1998;112(11):1058-60.
17
17. Brennan JA, Meyers AD, Jafek BW. The intraoperative management of the thyroid gland during laryngectomy. Laryngoscope. 1991; 101(9): 929-34.
18
18.Garas J, McGuirt WF. Squamous cell carcinoma of the subglottis. Am J Otolaryngol. 2006;27(1):1-4.
19
19. Kim JW, Han GS, Byun SS, Lee DY, Cho BH, Kim YM. Management of thyroid gland invasion in laryngopharyngeal cancer. Auris Nasus Larynx. 2008; 35(2):209-12.
20
20. Schultz NT. Trends and Patterns in the Ossification of Thyroid Cartilage. 2015.
21
21. Sion-Vardy N, Fliss DM, Prinsloo I, Shoham-Vardi I, Benharroch D. Neoangiogenesis in squamous cell carcinoma of the larynx - biological and prognostic associations. Pathol Res Pract. 2001; 197(1):1-5.
22
22. Lin P, Huang X, Zheng C, Cai Q, Guan Z, Liang F, et al. The predictive value of MRI in detecting thyroid gland invasion in patients with advanced laryngeal or hypopharyngeal carcinoma. Eur Arch Otorhinolaryngol. 2017;274(1):361-6.
23
ORIGINAL_ARTICLE
Comparing the Efficacy of Temperature-Controlled Radiofrequency Tonsil Ablation versus CO2-Laser Cryptolysis in the Treatment of Halitosis
Introduction: Halitosis and foreign body sensation are two common and disturbing symptoms of chronic caseous tonsillitis (CCT). The aim of this study was to compare the efficacy and safety of temperature-controlled radiofrequency (TC-RF) tonsil ablation with CO2-laser cryptolysis (CO2-LC) in the treatment of patients with halitosis caused by CCT. Materials and Methods: Sixty-two patients who suffered from halitosis and/or foreign body sensation due to CCT were enrolled in the present randomized clinical trial, and were randomly assigned into two groups. Group A underwent TC-RF tonsil ablation and Group B received CO2-LC. The severity of symptoms including halitosis and foreign body sensation was reported 7 days, 1 month, and 6 months after the procedure. Patient pain levels and amount of bleeding were evaluated as safety outcome measures. Pain levels were evaluated during the intervention, and at Day 1, 3, and 7 following the procedure using a visual analog scale (VAS). Results: Mean rank of pain score in the RF tonsil ablation group was found to be higher than in the CO2-LC group at all measured timepoints following the procedure. The amount of bleeding in the LC group was found to be significantly less than in the RF group (P<0.05). No significant difference was found between the groups regarding duration of procedure (P=0.157). Conclusion: Both procedures were found to be effective and safe in the treatment of CT-associated halitosis. However, LC showed better results based on lower pain levels, lower incidence of bleeding, and faster progression to a routine diet.
https://ijorl.mums.ac.ir/article_10706_0c1c394e966702d12f108692a46429dd.pdf
2018-05-01
159
166
10.22038/ijorl.2018.26844.1894
Halitosis
Laser
Pain
Tonsillitis
Farnaz
Hashemian
farnazhashemian@yahoo.com
1
Department of Otolaryngology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
AUTHOR
Hoda
Jafari Moez
h_jafarimoez@yahoo.com
2
Department of Otolaryngology,School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
AUTHOR
Mohammad Ali
Seif -Rabiei
seifrabiei@yahoo.cm
3
Department of Community Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
AUTHOR
Javaneh
Jahanshahi
jahanshahi287@gmail.com
4
Department of Otolaryngology,School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
LEAD_AUTHOR
1. Brook I, Yocum P, Foote PA. Changes in the core tonsillar bacteriology of recurrent tonsillitis: 1977–1993. Clin Infect Dis. 1995;21(1):171–6.
1
2. Ferguson M, Aydin M, Mickel J. Halitosis and the tonsils: A review of management. Otolaryngol Head Neck Surg. 2014;151(4):567–74.
2
3. Rosemberg M. Halitose: perspectivas em pesquisa. Rio de Janeiro: Ed. Guanabara Koogan SA; 2003.
3
4. Dal Rio AC, Franchi-Teixeira AR, Nicola EM. Relationship between the presence of tonsilloliths and halitosis in patients with chronic caseous tonsillitis. Br Dent J. 2008 26;204:E4.
4
5. Claesson R, Edlund MB, Persson S, Carlsson J. Production of volatile sulfur compounds by various Fusobacterium species. Molecular Oral Microbiology. 1990;5(3):137–42.
5
6. Al-Abbasi AM. Tonsillectomy for the treatment of halitosis. Niger J Med. 2009;18(3):295–8.
6
7. Finkelstein Y, Talmi YP, Ophir D, Berger G. Laser cryptolysis for the treatment of halitosis. Otolaryngol Head Neck Surg. 2004;131(4):372–7.
7
8. Ata N, Övet G, Alataş N. Effectiveness of radiofrequency cryptolysis for the treatment of halitosis due to caseums. Am J Otolaryngol. 2014; 35(2):93–8.
8
9. Passos CA, Altemani A, Nicola JH, Nicola EMD. Histopathological evaluation in biopsies of palatine tonsils submitted to cryptolysis by coagulation with CO2 laser for treatment of chronic caseous tonsillitis. Photomed Laser Surg. 2004; 22(3): 211–9.
9
10. Karadağ S, Özkiriş M, Kubilay U, Söyletir G. The effect of radiofrequency ablation on microbiology of the tonsils. Int J Pediatrc Otorhinolaryngol. 2012;76(11):1654–7.
10
11. Krespi YP, Kizhner V. Laser tonsil cryptolysis: in-office 500 cases review. Am J Otolaryngol. 2013(5); 34:420–4.
11
12. Passos CA, Oliveira F, Nicola JH, Nicola EM. Criptólise por Coagulação com Laser de CO2 em Tonsilite Crônica Caseosa: método conservador eresultados. Rev Bras Otorrinolaringol. 2002; 68(3): 405–10.
12
13. Dal Rio ACD, Passos CA, Nicola JH, Nicola EM. CO2 laser cryptolysis by coagulation for the treatment of halitosis. Photomed Laser Surg. 2006; 24(5):630–6.
13
14. Tanyeri HM, Polat S. Temperature-controlled radiofrequency tonsil ablation for the treatment of halitosis. Eur Arch Otorhinolaryngol. 2011; 268(2): 267–72.
14
15. Vogt K, Konuhova S, Peksis K, Markow J. Development and clinical evaluation of bipolar radiofrequency cryptolysis. Otorhinolaryngol Head Neck Surg 2016;2.
15
16. Brodsky L. Modern assessment of tonsils and adenoids.Pediatr Clin North Am.1989;36(6):1551-69.
16
ORIGINAL_ARTICLE
The Challenge of Vestibular Rehabilitation in a Patient with Bilateral Vestibular Dysfunction Following Surgery: A Case Report
Introduction:
Bilateral vestibular dysfunction (BVD) is an uncommon finding in vestibular assessment, and the combination of BVD and orthopedic problems represents a rare and challenging case for treatment.
Case Report:
The patient had several previous back surgeries and received gentamycin after surgery. After 6 months, she experienced continuous dizziness, unsteadiness and oscillopsia. The patient underwent complete vestibular assessment and received an individualized vestibular rehabilitation program for 9 months. She achieved a complete recovery from all symptoms and returned to active social function.
Conclusion:
Vestibular rehabilitation could be an effective treatment for complicated cases of BVD. Adaptation exercises may be useful in young patients with BVD.
https://ijorl.mums.ac.ir/article_10707_fb3900e75a30799b5cafc3327dc40d05.pdf
2018-05-01
167
170
10.22038/ijorl.2017.23203.1772
Adaptation
Bilateral vestibular dysfunction
Gentamicin
Ototoxicity
vestibular rehabilitation
Sadegh
Jafarzadeh
jafarzadehs@mums.ac.ir
1
Department of Audiology, School of Paramedical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran.
LEAD_AUTHOR
Mohammad Reza
Golrokhian Sani
golrokhianmd@gmail.com
2
Department of Otolaryngoloy, Sina Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
AUTHOR
1. Bittar RS, Pedalini ME, Ramalho JR, Carneiro CG. Bilateral vestibular loss after caloric irrigation: clinical application of vestibular rehabilitation. Rev Laryngol Otol Rhinol (Bord). 2005;126:3–6.
1
2. McGath JH, Barber HO, Stoyanoff S. Bilateral vestibular loss and oscillopsia. J Otolaryngol. 1989;18:218–21.
2
3. Guinand N, Boselie F, Guyot JP, Kingma H. Quality of life of patients with bilateral vestibulopathy. Ann Otol Rhinol Laryngol. 2012; 121: 471–7.
3
4. Sun DQ, Ward BK, Semenov YR, Carey JP, Della Santina CC. Bilateral Vestibular Deficiency: Quality of Life and Economic Implications. JAMA Otolaryngol Head Neck Surg. 2014;140:527–34.
4
5. Guinand N, Pijnenburg M, Janssen M, Kingma H. Visual acuity while walking and oscillopsia severity in healthy subjects and patients with unilateral and bilateral vestibular function loss. Arch Otolaryngol Head Neck Surg. 2012;138:301–6.
5
6. Zingler VC, Weintz E, Jahn K, Huppert D, Cnyrim C, Brandt T, et al. Causative factors, epidemiology, and follow-up of bilateral vestibulopathy. Ann NY Acad Sci. 2009;1164: 505–8.
6
7. Ward BK, Agrawal Y, Hoffman HJ, Carey JP, Della Santina CC. Prevalence and impact of bilateral vestibular hypofunction: results from the 2008 US National Health Interview Survey. JAMA Otolaryngol Head Neck Surg. 2013;139:803–10.
7
8. Brown KE, Whitney SL, Wrisley DM, Furman JM. Physical therapy outcomes for persons with bilateral vestibular loss. Laryngoscope.2001;111 (10):1812–7.
8
9. Porciuncula F, Johnson CC, Glickman LB. The effect of vestibular rehabilitation on adults with bilateral vestibular hypofunction: a systematic review. J Vestib Res. 2012;22:283–98.
9
10. Krebs DE, Gill-Body KM, Riley PO, Parker SW. Double-blind, placebo-controlled trial of rehabilitation for bilateral vestibular hypofunction: preliminary report. Otolaryngol Head Neck Surg. 1993;109:735–41.
10
11. Herdman SJ, Hall CD, Schubert MC, Das VE, Tusa RJ. Recovery of dynamic visual acuity in bilateral vestibular hypofunction. Arch Otolaryngol Head Neck Surg. 2007; 133:383–9.
11
12. Jafarzadeh S, Bahrami E, Pourbakht A, Jalaie S, Daneshi A. Validity and reliability of the Persian version of the dizziness handicap inventory. J Res Med Sci. 2014;19:769–75.
12
13. Alberts BB, Selen LP, Verhagen WI, Medendorp WP. Sensory substitution in bilateral vestibular a-reflexic patients. Physiol Rep. 2015;3: pii: e12385.
13
14. Scherer M, Migliaccio AA, Schubert MC. Effect of vestibular rehabilitation on passive dynamic visual acuity. J Vestib Res. 2008;18:147–57.
14
ORIGINAL_ARTICLE
Pediatric Inflammatory Myofibroblastic Tumors of the Airway: Two Case Reports with Varying Clinical Presentation
Introduction:
An inflammatory myofibroblastic tumor (IMT) is a rare tumor of intermediate malignant potential. It may occur in a wide range of anatomical locations. One-third are found in the respiratory tract. We report two cases of IMT of the airway diagnosed at our institution.
Case Report:
Case 1: A 6-year-old male child presented with a 1-month history of hoarseness of the voice. On evaluation, a polypoid nodule was noted in the right vocal cord which was excised through the endolaryngeal route. Histopathology was suggestive of anaplastic lymphoma kinase (ALK)-negative IMT. He presented with recurrence after 4 months, for which he underwent endolaryngeal reexcision and tracheostomy for airway protection. A third recurrence after 6 months was managed with laser excision, and the patient was started on oral celecoxib. After 1.5 years of follow up, endoscopic examination showed no recurrence, and celecoxib was continued. Case 2: A 7-year-old male child presented with cough and respiratory distress. Bronchoscopy and high resolution computed tomography showed a polypoidal lesion with calcification arising from the left anterolateral wall of the trachea with significant narrowing of the lumen. The patient underwent biopsy followed by endoscopic excision, and was diagnosed with IMT. Currently the patient is under follow up with no recurrence.
Conclusion:
IMT indicates a proliferative myofibroblastic growth. Surgical resection should be recommended for all lesions if not prohibited by anatomic location or morbidity. Patients should be followed up closely for recurrence. In most cases, complete surgical excision will suffice; however multiple recurrences can be managed with chemotherapy. These two cases highlight the importance of a multidisciplinary approach in rare tumors in difficult anatomical locations.
https://ijorl.mums.ac.ir/article_10708_bb764d4d8511d6172f23cb61a5fce176.pdf
2018-05-01
171
176
10.22038/ijorl.2017.22449.1740
Airway
Children
Inflammatory
Myofibroblastic
Recurrence
Nuthan
Kumar
nuthanraga28@gmail.com
1
Department of Pediatric Hematology and Oncology, Kanchi Kamakoti Childs Trust Hospital And The Childs Trust Medical Research Foundation, Nungambakkam, Chennai – 600034,Tamil Nadu State, India.
LEAD_AUTHOR
Thirunavukkarasu
Saravanamuthu
thiruairway@gmail.com
2
Department of Pediatric ENT, Kanchi Kamakoti Childs Trust Hospital And The Childs Trust Medical Research Foundation, Nungambakkam, Chennai – 600034,Tamil Nadu State, India.
AUTHOR
Arathi
Srinivasan
drarathi@gmail.com
3
Department of Pediatric Hematology and Oncology, Kanchi Kamakoti Childs Trust Hospital And The Childs Trust Medical Research Foundation, Nungambakkam, Chennai – 600034,Tamil Nadu State, India.
AUTHOR
Thulasiraman
Ramalingam
drthulas31@gmail.com
4
Department of Pathology, Kanchi Kamakoti Childs Trust Hospital And The Childs Trust Medical Research Foundation, Nungambakkam, Chennai – 600034,Tamil Nadu State, India.
AUTHOR
Julius-Xavier
Scott
jxscott@hotmail.com
5
Department of Pediatric Hematology and Oncology, Kanchi Kamakoti Childs Trust Hospital And The Childs Trust Medical Research Foundation, Nungambakkam, Chennai – 600034,Tamil Nadu State, India.
AUTHOR
1. Coffin CM, Hornick JL, Fletcher CDM. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohisto- chemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol 2007; 31:509–20.
1
2. Coffin CM, Watterson J, Priest JR, Dehner LP. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol 1995;19(8):859–72.
2
3. Mehta B, Mascarenhas L, Zhou S, Wang L, Venkatramani R. Inflammatory Myofibroblastic Tumors in Childhood. Pediatr Hematol Oncol 2013; 30:640–5.
3
4. Johnson K, Notrica DM, Carpentieri D, Jaroszewski D, Henry MM. Successful Treatment of Recurrent Pediatric Inflammatory Myofibroblastic Tumor in a Single Patient With a Novel Chemotherapeutic Regimen Containing Celecoxib. J Pediatr Hematol Oncol 2013;35:414-16.
4
5. Anthony PP. Inflammatory pseudotumor (plasma cell granuloma) of lung, liver and other organs. Histopathology. 1993;23:501–503.
5
6. Brodlie M, Barwick SC, Wood KM, McKean MC, Welch A. Inflammatory myofibroblastic tumours of the respiratory tract: paediatric case series with varying clinical presentations. J Laryngol Otol 2011; 125: 865–8.
6
7. Hoover SV, Granston AS, Koch DF, et al. Plasma cell granuloma of the lung, response to radiation therapy. Cancer 1976;39:123–5.
7
8. Kovach SJ, Fischer AC, Katzman PJ, Salloum RM, Ettinghausen SE, Madeb R, et al. Inflammatory myofibroblastic tumors. J Surg Oncol 94:385–91.
8
9. Uchida DA, Hawkins JA, Coffin CM, Grimmer JF. Inflammatory myofibroblastic tumor in the airway of a child. Ann Thorac Surg 2009;87: 610–13.
9
10. Wenig BM, Devaney K, Bisceglia M. Inflammatory myofibroblastic tumor of the larynx. A clinicopathologic study of eight cases simulating a malignant spindle cell neoplasm. Cancer 1995; 76: 2217–29.
10
11. Alhumaid H, Bukhari M, Rikabi A, Farahat M, Mesallam TA, Malki KH, et al. Laryngeal myofibroblastic tumor: case series and literature review. Int J Health Sci (Qassim). 2011; 5:187–95.
11
12. Das Purkayastha PK, Hartley BE, Sebire NJ. Airway obstruction due to a retro-tracheal inflammatory myofibroblastic tumour in a 19-month old boy. Int J Pediatr Otorhinolaryngol. Extra 2009; 4:25–8.
12
13. Kumar S, Gupta AK, Kakkar N. Inflammatory myofibroblastic tumor larynx mimicking laryngeal papillomatosis. Int J Pediatr Otorhinolaryngol Extra 2009;4 :42–4.
13
14. Mandelbaum I, Brashear RE, Hull MT. Surgical treatment and course of pulmonary pseudotumor (plasma cell granuloma). J Thorac Cardiovasc Surg 1981; 82:77–82.
14
15. Corsi A, Ciofalo A, Leonardi M et al. Recurrent inflammatory myofibroblastic tumor of the glottis mimicking malignancy. Am J Otolaryngol 1997; 18:121–6.
15
16. Przkora R, Bolder U, Schwarz S, Jauch KW, Spes J, Andreesen R et al. Regression of nonresectable inflammatory myofibroblastic tumours after treatment with nonsteroidal anti-inflammatory drugs. Eur J Clin Invest 2004; 34: 320–1.
16
17. Hakozaki Y, Katou M, Nakagawa K, Shirahama T, Matsumoto T. Improvement of inflammatory pseudotumor of the liver after nonsteroidal antiinflammatory agent therapy. Am J Gastroenterol 1993; 88:1121–2.
17
18. Yun-Lu Tao, Zhen-Jun Wang, Jia-Gang Han, Wei P. Inflammatory myofibroblastic tumor successfully treatedwith chemotherapy and nonsteroidals: A case report. World J Gastroenterol2012; 18:7100–3.
18
19. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306–11.
19
20. Butrynski JE, D’Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010; 363: 1727–33.
20
21. Giuriato S, Faumont N, Bousquet E, Foisseau M, Bibonne A, Moreau M et al. Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy. Cancer Biol Ther.2007; 6: 1318–23.
21
ORIGINAL_ARTICLE
Pneumocephalus after Tympanomastoidectomy: A Case Presentation
Introduction: Pneumocephalus is the presence of air or gas within the cranial cavity. It can occur following otorhinolaryngological procedures. A small pneumocephalus spontaneously heals without any treatment. In severe cases, conservative therapy includes a 30-degree head elevation, avoidance of the Valsalva maneuver, analgesics, osmotic diuretics, and oxygen therapy. Case Report: A 56-year-old woman was referred to the emergency department due to a severe headache in the frontal area for 2 days before admission. The patient experienced nausea and vomiting in the morning and had no history of seizures or decreased consciousness. Examination of neurological symptoms was completely normal and showed no symptoms of meningeal irritation. In terms of past history, the patient had undergone tympanomastoidectomy surgery and resection of the cholesteatoma 1 week previously. The Mount Fuji sign was found on the brain computed tomography (CT) scan of the patient. Treatments such as CBR (complete bed rest), 30-degree head elevation, anti-fever, analgesics and oxygen therapy, along with anti-compulsive drug (phenytoin), were prescribed. At the end of 5 days, the patient's pneumocephalus was resolved completely. Conclusion: Pneumocephalus should be considered a post-operative complication of tympanomastoidectomy. In most cases, pneumocephalus responds to conservative therapy. Supplemental oxygen increases the rate of absorption of pneumocephalus. Serial imaging is needed to ensure gradual reduction of the pneumocephalus.
https://ijorl.mums.ac.ir/article_10709_b349c1b3ce213471e596190c9e23a744.pdf
2018-05-01
177
180
10.22038/ijorl.2018.27854.1913
Mount Fuji sign
Mastoidectomy
Pneumocephalus
Mohammad Hossein
Baradaranfar
baradaranfar@yahoo.com
1
Department of Otolaryngology- Head and Neck Surgery, Otorhinolaryngology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
AUTHOR
Sedighe
Vaziribozorg
s.vaziribozorg1408@gmail.com
2
Department of Otolaryngology- Head and Neck Surgery, Otorhinolaryngology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
AUTHOR
Mojtaba
Mirzadeh
m.mirzade2017@gmail.com
3
Department of Otolaryngology- Head and Neck Surgery, Otorhinolaryngology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
LEAD_AUTHOR
Mostafa
Salari
m.salari@gmail.com
4
Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
AUTHOR
1. Kuo M-Y, Lien W-C, Wang H-P, Chen W-J. Nontraumatic tension pneumocephalus – a differential diagnosis of headache at the ED. Am J Emerg Med. 2005; 23(2):235–6.
1
2. Sawant R, Trinidade A, Das T. A spontaneous Pneumocephalus and Hyperpneumatisation of occipital bone and atlas vertebra: a case report. IOSR Journal of Dental and Medical Sciences.2016; 15(8):11-4.
2
3. Schirmer CM, Heilman CB, Bhardwaj A. Pneumocephalus: case illustrations and review. Neurocrit care. 2010; 13(1):152–8.
3
4. Wolff E. Air accumulation in the right lateral ventricle of the brain (Pneumocephalus) (article in German). Münch Med Wochenschr.1914; 61:899.
4
5. Ectors L. Chronic subdural hematoma. Surgical treatment (article in French) Acta Chir Belg. 1962; 6: 570–606.
5
6. Solomiichuk VO, Lebed VO, Drizhdov KI. Posttraumatic delayed subdural tension pneumocephalus. Surg Neurol Int. 2013; 4:37.
6
7. Ruiz-Juretschke F, Mateo-Sierra O, Iza-Vallejo B, Carrillo-Yagüe R. Intraventricular tension pneumocephalus after transsphenoidal surgery: A case report and literature review. Neurocirugia (Astur). 2007; 18 (2):134–7.
7
8. Aoki N, Sakai T. Computed tomography features immediately after replacement of haematoma with oxygen through percutaneous subdural tapping for the treatment of chronic subdural haematoma in adults. Acta Neurochir. 1993; 120(1-2):44–6.
8
9. Monajati A, Cotanch WW. Subdural tension pneumocephalus following surgery. J Comput Assist Tomogr. 1982;6(5):902–6.
9
10. Karavelioglu E, Eser O, Haktanir A. Pneumocephalus and pneumorrhachis after spinal surgery: Case report and review of the literature. Neurol Med Chir. 2014;54(5):405–7.
10
11.Ishiwata Y, Fujitsu K, Sekino T, Fujino H, Kubokura T, Tsubone K, et al. Subdural tension pneumocephalus following surgery for chronic subdural hematoma. J Neurosurg. 1988; 68(1): 58–61.
11
12. Agrawal A, Singh BR. Mount Fuji sign with concavo-convex appearance of epidural haematoma in a patient with tension pneumocephalus. J Radiol Case Rep. 2009; 3 (1):10–2.
12
13. Kankane VK, Jaiswal G, Gupta TK. Posttraumatic delayed tension pneumocephalus: Rare case with review of literature. Asian J Neurosurg. 2016; 11(4):343–7.
13
14. Penrose-Stevens A, Ibrahim A, Redfern R. Localized pneumocephalus caused by Clostridium perfringens meningitis. Br J Neurosurg. 1999; 13(1):85–6.
14
15. Dubey SP, Jacob O, Gandhi M. Postmasto- idectomy pneumocephalus: case report. Skull Base. 2002; 12(3):167–73.
15
16. Lee DH, Cho HH, Cho YB. Pneumocephalus secondary to mastoid surgery: A case report. Auris Nasus Larynx. 2007; 34(1):91-3.
16
17. Bernstein AL, Cassidy J, Duchynski R, Eisenberg SS. Atypical headache after prolonged treatment with nasal continuous positive airway pressure. Headache: The Journal of Head and Face Pain. 2005; 45(5):609-11.
17
18. Paiva-NetoMAd, Tella-Jr OId.Supra-orbital keyhole removal of anterior fossa and parasellar meningiomas. Arquivos de neuro-psiquiatria. 2010; 68(3):418-23.
18
ORIGINAL_ARTICLE
Complication of an Odontogenic Infection to an Orbital Abscess: The Role of a Medical Fraudster (“Quack”)
Introduction: Complication of an odontogenic infection to an orbital abscess is not a common presentation. The progression from a simple toothache to a condition that may lead to loss of vision is sudden and severe. Case Report: We report a rare case in which a patient developed facial cellulitis that progressed to orbital abscess after unsterile dental manipulation by a medical fraudster (“quack”). The patient was initiated on high-grade antibiotics, which resolved the facial cellulitis. However, the patient developed orbital abscess with restricted mobility of the right eye in the lateral gaze. After radiological confirmation of the abscess, it was drained by an external approach. Due to timely intervention, the extra-ocular mobility was regained, and the vision remained unaffected. Conclusion: Knowledge of the routes of the spread of dental infection to the vital structures and the urgent need for aggressive multidisciplinary management is paramount. Furthermore, awareness of the rising quack culture in developing nations needs to be increased.
https://ijorl.mums.ac.ir/article_10710_6dcd2abf7cbbd554f48214d25be6fdad.pdf
2018-05-01
181
184
10.22038/ijorl.2017.20807.1775
Orbital abscess
odontogenic infection
facial cellulitis
Nikhil
Arora
for_nikhilarora@yahoo.com
1
Department of Otorhinolaryngology and Head and Neck Surgery, Maulana Azad Medical College and Associated Lok Nayak Hospital, New Delhi-110002, India.
AUTHOR
Ruchika
Juneja
junejaruchika1@gmail.com
2
Department of Otorhinolaryngology and Head and Neck Surgery, Maulana Azad Medical College and Associated Lok Nayak Hospital, New Delhi-110002, India.
LEAD_AUTHOR
Ravi
Meher
ravimeher@gmail.com
3
Department of Otorhinolaryngology and Head and Neck Surgery, Maulana Azad Medical College and Associated Lok Nayak Hospital, New Delhi-110002, India.
AUTHOR
1. Bizakis JG, Chariton E, Papadakis MD, Panos Prassopoulos MD, Dionysios E, Kyrmizakis MD. et al. Transantral evacuation of an orbital abscess following a molar toothn extraction. Am J Otolaryngol. 1997;18(4):277–9.
1
2. Kim IK, Kim JR, Jang KS. Orbital abscess from an odontogenic infection. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103(1):1–6.
2
3. Sicher H, DuBrul EL. Oral Anatomy, 7th ed. St. Louis, CV Mosby, 1980. pp 498–518.
3
4. Brook I. Sinusitis of odontogenic origin. Otolaryngol Head Neck Surg. 2006;135(3):349–55.
4
5. Thakar M, Thakar A. Odontogenic orbital cellulitis – Report of a case and considerations on route of spread. Acta Ophthalmol Scand. 1995; 73(5): 470–1.
5
6. Bullock JD, Fleishman JA. The spread of odontogenic infections to the orbit: diagnosis and management. J Oral Maxillofac Surg. 1985; 43(10): 749–55
6
7. Poon TL, Lee WY, Ho WS, Pang KY, Wong CK. Odontogenic subperiosteal abscess of orbit: a case report. J Clin Neurosci 2001; 8:469-71.
7
8. Vijayan A, Sreejith VP, Ranjini, Ahamed G. Orbital abscess arising from an odontogenic infection. J Contemp Dent Prac. 2012; 13(5):740-3.
8
9. Miller H, Kassebaum DK. Managing periorbital space abscess secondary to dentoalveolar abscesses. JADA. 1995; 126(4):469–72.
9